Rega marang bathi mangsa ngarep Jupiter Neurosciences, Inc. (JUNS)
Jupiter Neurosciences Inc (JUNS) strong scientific foundation in brain molecule delivery drives the dynamics of the company's expected P/E ratio, which currently stands at 0.00. Business development relies on a trial schedule that remains independent of GDP. The proprietary oral administration system protects yields from dumping, as clearly illustrated by this multiplier chart.
Ringkesan rincian data analitis jupiterneurosciences.com (JUNS)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator total utang lan likuiditas perusahaan:
Total Utang marang Modal Jupiter Neurosciences Inc|JUNS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Jupiter Neurosciences|JUNS - Kewajiban utang agregat|Utang marang nilai buku Jupiter Neurosciences, Inc.|JUNS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Jupiter Neurosciences|Rasio cepet jupiterneurosciences.com
- statistik bathi lan rasio pasar:
JUNS - Penghasilan resik perusahaan|Bathi mangsa ngarep Jupiter Neurosciences Inc|JUNS - Pangali P/E|Rega marang bathi mangsa ngarep Jupiter Neurosciences Inc|JUNS - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Jupiter Neurosciences, Inc.|JUNS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Jupiter Neurosciences|JUNS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan jupiterneurosciences.com|JUNS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Jupiter Neurosciences Inc
- data pendapatan lan penerimaan dodolan:
Pambiji fundamental:Jupiter Neurosciences Inc JUNS
To protect capital during periods of turbulence, it is crucial for investors to monitor the ratio of the current market value of Jupiter Neurosciences Inc (JUNS) to its expected annual earnings, as reflected in the fluctuations of the company's forward P/E. This indicator captures the dynamics of future income revaluation, confirming the business's status as a defensive asset due to stable demand for biotechnology that remains independent of global macroeconomic cycles.
Pesaing langsung
Prakiraan rega marang bathi BIIB (Biogen)|Pangali Forward P/E Neurocrine (NBIX)|Rega marang bathi mangsa ngarep Regencell RGC|AXSM (Axsome Corp) - Rasio rega marang bathi sing dikarepake|ACADIA Pharmaceuticals - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi xenon-pharma.com XENE|VKTX (Viking Therapeutics, Inc.) - Prakiraan rega marang bathi|SUPN: Rasio kapitalisasi marang bathi mangsa ngarep|CPRX (Catalyst Pharmaceuticals Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Denali Corp DNLI|Rega marang bathi mangsa ngarep Harmony Biosciences (HRMY)|BHVN (biohavenpharma.com) - Pangali mangsa ngarep rega marang bathi|Amylyx Pharmaceuticals, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi TRVI|PRAX - Rega marang bathi mangsa ngarep|AVXL (Anavex Life Sciences Corp) - Rasio rega marang bathi mangsa ngarep|CBLL: Pangali Forward P/E|Rasio prakiraan rega marang bathi Prothena (PRTA)|Prakiraan rega marang bathi ALEC|Pangali Forward P/E Annexon Biosciences|Rega marang bathi mangsa ngarep Omeros Corporation (OMER)|NGNE (Neurogene Therapeutics) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep AC Immune ACIU|voyagertherapeutics.com (VYGR) - Rasio prakiraan rega marang bathi|NMRA - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Scilex Holding SCLX|TVGN: Pangali Forward P/E|Prakiraan rega marang bathi Alpha Cognition Inc.|CGTX (Cognition Therapeutics) - Pangali Forward P/E|inhibikase.com (IKT) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E SAVA|ASRT - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Coya Therapeutics COYA|VTGN: Rasio rega marang bathi mangsa ngarep|Ovid Rx - Pangali Forward P/E|acumenpharm.com (ABOS) - Prakiraan rega marang bathi|CRVO: Pangali Forward P/E|Rasio prakiraan rega marang bathi Alterity Therapeutics Limited (ATHE)|Rega marang bathi mangsa ngarep Clene Inc|PepGen Corp (PEPG) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi RLMD (Relmada Therapeutics)|ANVS (annovisbio.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E GRCE (Grace Therapeutics)|Kapitalisasi marang proyeksi bathi Firefly Neuroscience, Inc. (AIFF)|KLTO - Rega marang bathi mangsa ngarep|NRSN (NeuroSense Therapeutics) - Rasio rega marang bathi mangsa ngarep|RVPH: Pangali Forward P/E|Prakiraan rega marang bathi MetaVia|Rega marang bathi mangsa ngarep NeurAxis|HSDT (Helius Medical Technologies Inc.) - Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi PASG (Passage Bio, Inc.)|Pangali Forward P/E bionomics.com.au (NEUP)|Rega marang bathi mangsa ngarep Minerva Neurosciences NERV|ATHA: Rasio rega marang bathi mangsa ngarep|ADXN - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Alzamend Neuro, Inc. ALZN|cyclerion.com (CYCN) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep PTIX|KTTA (Pasithea Therapeutics Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Cortigent Medical CRGT|Prakiraan rega marang bathi ATXI (Avenue Therapeutics, Inc.)|Pangali Forward P/E Brainstorm Cell Therapeutics Inc. (BCLI)|Rega marang bathi mangsa ngarep Cara Therapeutics, Inc CARA|Pangali mangsa ngarep rega marang bathi CHRO|ELYM - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Intra-Cellular Therapies|Longboard Pharmaceuticals, Inc. (LBPH) - Rega marang bathi mangsa ngarep|MRNS: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi NKGN|Pangali Forward P/E NeuroBo Pharma|Rega marang bathi mangsa ngarep Sage Therapeutics, Inc. (SAGE)|SNPX: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E TRVN (Trevena)|Kapitalisasi marang proyeksi bathi Vigil Neuroscience Inc. (VIGL)|WENA: Prakiraan rega marang bathi|Cerevel Corp - Rasio kapitalisasi marang bathi mangsa ngarep
